阅读说明：本技术 一种提高人凝血因子ix表达水平的方法 (Method for improving expression level of human blood coagulation factor IX ) 是由 姜舒 熊斌 张芸 于 2019-12-25 设计创作，主要内容包括：本发明公开了一种提高人凝血因子IX表达水平的方法,包括优化人凝血因子IX基因；替换Kozak序列；利用优化后的人FIX基因和Kozak序列构建腺相关病毒(AAV)表达质粒并包装重组AAV；本发明使用优化后的基因编码序列和Kozak序列,显著地提高了人凝血因子FIX基因的表达水平。该优化的人FIX基因和Kozak序列可用于高效生产治疗B型血友病的FIX蛋白,降低FIX蛋白的生产成本；也可用于AAV介导的基因替代疗法治疗B型血友病,提高FIX基因在人体内的表达水平,从而减少给药剂量,提高治疗效果。(The invention discloses a method for improving the expression level of human blood coagulation factor IX, which comprises optimizing human blood coagulation factor IX genes; replacement of Kozak sequence; constructing an adeno-associated virus (AAV) expression plasmid by using the optimized human FIX gene and a Kozak sequence, and packaging the recombinant AAV; the invention uses the optimized gene coding sequence and the Kozak sequence to obviously improve the expression level of the human blood coagulation factor FIX gene. The optimized human FIX gene and Kozak sequence can be used for efficiently producing FIX protein for treating hemophilia B, and the production cost of the FIX protein is reduced; can also be used for AAV-mediated gene replacement therapy for treating hemophilia B, and can increase expression level of FIX gene in human body, thereby reducing administration dosage and improving therapeutic effect.)

1. A method of increasing the expression level of human coagulation factor IX comprising the steps of:

step 1, codon optimization of gene IX.

Step 2, replacing a Kozak sequence, wherein the replaced Kozak sequence is GCCGCCACCATGC, and ATG is the initiation codon of the IX gene; the optimized IX gene was expressed using the Kozak sequence.

And 3, preparing recombinant adeno-associated virus rAAV, and transfecting plasmids or infecting HEK293T or HepG2 cells by the rAAV.

2. The method for increasing the expression level of human coagulation factor IX according to claim 1, wherein the recombinant adeno-associated virus rAAV is prepared, plasmid is transfected or rAAV is infected into HEK293T or HepG2 cells

1) The enzyme digestion reaction system is as follows:

DNA 1μg

10×Buffer 5μL

notl restriction enzyme 1. mu.L

ddH₂O to 50. mu.L

The reaction conditions are as follows:

37℃，1-16h

2) and (3) fragment recovery: the reaction solution after the digestion was subjected to agarose gel electrophoresis, and the agarose concentration was 1%. The electrophoresis parameters are as follows: voltage 120V, time 30 min. Cutting the target fragment under ultraviolet light; recovering the target DNA by using a gel recovery kit; detecting the concentration of the recovered DNA by using a micro spectrophotometer;

3) connection of

The connection reaction system is as follows:

linearized AAV vector 100ng

The proper amount of the expression sequence of the linearized FIX is 3 to 10 times of the mol amount of the linearized AAV vector and 10 XT 4 DNA ligaseBuffer 1.5 mu L

T4 DNA ligase 1μL

ddH₂O to 15. mu.L

The reaction conditions are as follows: at 16 ℃ for 4-16h

4) Coli Stbl4 transformed competent cells

Freezing a tube of E.coli Stbl4 transformation competent cells (100. mu.L) at-80 deg.C, thawing in ice, and adding 10. mu.L of the ligation reaction solution; flicking the tube wall to mix well, ice-bathing for 30min, heat-shocking for 45s at 42 ℃, ice-bathing for 2min, and adding 1mL LB culture medium; recovering at 200rpm for 30-60min, spreading appropriate amount of bacteria liquid on LB plate containing 100 μ g/mL ampicillin, and culturing at 37 deg.C for 16 hr;

5) plasmid identification

Colonies on an LB plate are picked and inoculated into LB liquid culture containing 100 mu g/mL ampicillin, and the primary identification is carried out by using a PCR method, and the identification primer sequences are as follows:

upstream primer (seqF): TAGTCCTGTCGGGTTTCG

Downstream primer (seqR): TACAGGGCGCGTACTATG

The PCR reaction system is as follows:

EasyTaq 2×Mix 10μL

seqF(10μM)1μL

seqR(10μM)1μL

bacterial liquid 1. mu.L

ddH₂O 7μL

Total volume 20. mu.L

The PCR reaction program is:

95℃10min

94℃30s

58℃30s

72℃60s

35 cycles of reaction from step 2 to step 4

72℃2min

After the PCR reaction is finished, identifying by using 1% agarose gel electrophoresis; the voltage of electrophoresis is 120V, and the time is 30 min; after electrophoresis is finished, observing an electrophoresis result by using an ultraviolet gel imager; and selecting a colony with the PCR band size of 4419bp, and further performing sequencing verification to finally obtain the target plasmid.

3. The method of claim 1, wherein the replacement Kozak sequence is prepared by: the replacement Kozak sequence was embedded in a primer with the following sequence:

10F：CAATCTGCTAGCCGCCACCATGGAGAGGGTGAACATGATCATGGCT

10R：CCCTCTCCATGGTGGCGGCTAGCAGATTGTGAAAGTGGTATTCA

11F：CAATCTGCTAGCCGCCACCATGCAGAGGGTGAACATGATCATGGCT

11R：CCCTCTGCATGGTGGCGGCTAGCAGATTGTGAAAGTGGTATTCA

carrying out PCR by taking 10F and 10R as primers, pAAV-F9 as a template, 11F and 11R as primers and pAAV-F9 as a template;

the PCR reaction system is as follows:

dd H₂O，31μL

5×Takara PrimeSTAR Bufer，10μL

dNTP(2.5mM)，4μL

DMSO(100％)，1.5μL

forward primer (10. mu.M), 1. mu.L

Downstream primer (10. mu.M), 1. mu.L

Plasmid (1-10 ng/. mu.L), 1. mu.L

PrimeSTAR DNA polymerase，0.5μL

Total volume, 50 μ L

The PCR reaction procedure was as follows:

98℃，10s

55℃，5s

72℃，7min

the first to third steps were carried out for 30 cycles.

And cutting and recycling the PCR product, and connecting into circular plasmids by using a seamless connection kit. Coli stbl4 competent cells were transformed and the correct transformants were identified.

4. The method of claim 1, wherein the recombinant adeno-associated virus is prepared by the method comprising the steps of:

1) recombinant AAV packaging and purification

Adopting a three-plasmid packaging system, comprising the AAV expression plasmid, the helper plasmid pHelper and the packaging plasmid pRC 2/8;

the HEK293T cells are inoculated in 5 culture dishes of 15cm, after 12-18h, the cell confluence reaches 85-90%, and the cell state is good; changing the culture medium into a serum-free DMEM culture medium 1-2h before transfection;

preparing a DNA-PEI complex: sequentially adding 124 mu g of pHelper plasmid, 76 mu g of pRC2/8 plasmid and 65.1 mu g of pAAV-F9 plasmid into 5mL of DMEM medium, and mixing by vortexing; adding 1mL of PEI with the concentration of 1mg/mL into 5mL of DMEM medium, and uniformly mixing by vortex; and adding the PEI solution into the plasmid solution, uniformly mixing by vortex, and standing for 20min at room temperature. The DNA-PEI mixture was dropped into HEK293T cells and gently mixed. After 4-6h, the FBS-free culture medium is replaced by a FBS-containing complete culture medium;

and (3) 96h after transfection, respectively collecting culture medium supernatant and cells, and carrying out ultrasonic disruption after freeze thawing of the cells. The virus was purified by iodixanol density gradient centrifugation and concentrated using a 100KD ultrafiltration tube. After the titer was determined by qPCR, the samples were stored at-80 ℃;

2) infection with AAV

HepG2 cells were seeded in 24-well plates at a cell number of 4 × 10⁴One/well, medium volume 500. mu.L/well. 12-1 after inoculationAdding 50 μ L of culture medium containing the rAAV virus into culture well, and mixing to make multiplicity of infection (MOI) 10⁵、10⁶、0.5×10⁷. After 4-6h, 500. mu.L of the medium was supplemented. After 72h infection, the medium was collected, centrifuged at 1000g for 5min and the supernatant was removed.

5. The method according to claim 1, wherein the optimized factor IX gene retains all 8 exons except the intron which is the first intron.

Technical Field

The invention relates to the field of biochemistry, in particular to a method for improving the expression level of recombinant human coagulation factor FIX by optimizing a Kozak sequence and a codon of a coding gene

Technical Field

Hemophilia B is an X-linked hereditary blood disease. The factor IX cannot be normally synthesized due to mutation of FIX gene encoding the factor IX on the X chromosome of the patient. Clinically, the blood coagulation time is prolonged, spontaneous bleeding occurs in severe cases, and the blood coagulation time is at risk of teratogenesis and disability and even endangers life. At present, the replacement therapy mainly depends on the supplementation of active blood coagulation factor IX, the lifelong administration is needed, and no cure method exists.

The coding gene of human blood coagulation factor IX is located on the X chromosome, has a full length of 33.5kb, and comprises 8 exons and 7 introns; the total length of the mRNA is 2802 bp; the blood coagulation factor IX consists of 461 amino acids, which comprises a signal peptide with 28 amino acids at the N end and mediates the secretion of FIX protein into blood; the half-life of FIX protein in human blood is about 24 h.

The concentration of FIX protein in normal human plasma is about 5 mg/L. When the concentration of FIX protein in human plasma is 5-40% of the normal concentration, mild hemophilia symptoms are exhibited, which may cause severe bleeding at major surgery; when the concentration of FIX protein in human plasma is 1-5% of the normal concentration, moderate hemophilia symptoms are exhibited, which may cause severe bleeding at minor surgery or trauma; when the concentration of FIX protein in human plasma is lower than 1% of the normal concentration, severe hemophilia symptoms are exhibited and spontaneous bleeding occurs. Long-term spontaneous bleeding can lead to joint distortion or disability, and intracranial bleeding can even be life threatening.

The prevalence of hemophilia B in men is about 1/25000, and there is no cure, and there are two main methods for treating the disease: 1) transfusions replenish FIX in the plasma of patients. The method brings risk of blood infectious diseases to the transfused person, and long-term transfusion can cause the accumulation of iron element in the body. 2) The injection of the recombinant human FIX protein has the administration period of 1-3 times per week, and has high treatment cost and great economic burden on patients.

In order to make up the defects of the prior art, the invention aims to develop a method for improving the in vitro expression level of the recombinant human FIX protein, and the in vitro recombinant human FIX protein is used for treating the hemophilia B, so that the risk of blood infectious diseases caused by long-term blood transfusion can be avoided, the production cost of the recombinant human FIX protein can be reduced, and the method has important significance for gene therapy of the hemophilia B.

Disclosure of Invention

The purpose of the invention is realized by the following technical scheme: carrying out codon optimization on the human FIX gene, replacing the original Kozak sequence of the human FIX gene with a section of more efficient Kozak sequence, and packaging the recombinant AAV by using the AAV expression vector.

Further, the optimized Kozak sequence is GCCGCCACCATGC, wherein the bold ATG is the start codon of FIX gene.

Further, the human FIX gene had removed other introns except the first Intron I, and retained all 8 exons.

Further, the optimized FIX gene sequence is shown as Seq1 below.

Seq 1: FIX Gene sequences

ATGCAGCGCGTGAACATGATCATGGCCGAGAGCCCCGGCCTGATCACCAT CTGCCTGCTGGGCTACCTGCTGAGCGCCGAGTGCACCGGTTTGTTTCCTTTTTT ATAATACATTGAGTATGCTTGCCTTTTAGATATAGAAATATCTGATTCTGTCTTCTT CACTAAATTTTGATTACATGATTTGACAGCAATATTGAAGAGTCTAACAGCCAGCACCCAGGTTGGTAAGTACTGGTTCTTTGTTAGCTAGGTTTTCTTCTTCTTCACTT TTAAAACTAAATAGATGGACAATGCTTATGATGCAATAAGGTTTAATAAACACTG TTCAGTTCAGTATTTGGTCATGTAATTCCTGTTAAAAAACAGTCATCTCCTTGGTT TAAAAAAATTAAAAGTGGGAAAACAAAGAAATAGCAGAATATAGTGAAAAAAA ATAACCACAGTATTTTTGTTTGGACTTACCACTTTGAAATCAAATTGGGAAACAA AAGCACAAACAGTGGCCTTATTTACACAAAAAGTCTGATTTTAAGATATGTGAC AATTCAAGGTTTCAGAAGTATGTAAGGAGGTGTGTCTCTAATTTTTTAAATTATAT ATCTTCAATTTAAAGTTTTAGTTAAAACATAAAGATTAACCTTTCATTAGCAAGCT GTTAGTTATCACCAAAGCTTTTCATGGATTAGGAAAAAATCATTTTGTCTCTATCT CAAACATCTTGGAGTTGATATTTGGGGAAACACAATACTCAGTTGAGTTCCCTA GGGGAGAAAAGCAAGCTTAAGAATTGACACAAAGAGTAGGAAGTTAGCTATT GCAACATATATCACTTTGTTTTTTCACAACTACAGTGACTTTATTTATTTCCCAGA GGAAGGCATACAGGGAAGAAATTATCCCATTTGGACAAACAGCATGTTCTCAC AGTAAGCACTTATCACACTTACTTGTCAACTTTCTAGAATCAAATCTAGTAGCTG ACAGTACCAGGATCAGGGGTGCCAACCCTAAGCACCCCCAGAAAGCTGACTGG CCCTGTGGTTCCCACTCCAGACATGATGTCAGCTGTGAAATCCACCTCCCTGGA CCATAATTAGGCTTCTGTTCTTCAGGAGACATTTGTTCAAAGTCATTTGGGCAAC CATATTCTGAAAACAGCCCAGCCAGGGTGATGGATCACTTTGCAAAGATCCTCA ATGAGCTATTTTCAAGTGATGACAAAGTGTGAAGTTAAGGGCTCATTTGAGAAC TTTCTTTTTCATCCAAAGTAAATTCAAATATGATTAGAAATCTGACCTTTTATTACT GGAATTCTCTTGACTAAAAGTAAAATTGAATTTTAATTCCTAAATCTCCATGTGTA TACAGTACTGTGGGAACATCACAGATTTTGGCTCCATGCCCTAAAGAGAAATTG GCTTTCAGATTATTTGGATTAAAAACAAAGACTTTCTTAAGAGATGTAAAATTTT CATGATGTTTTCTTTTTTGCTAAAACTAAAGAATTATTCTTTTACATTTCAGTGTTC CTGGACCACGAGAACGCCAACAAGATCCTGAACCGCCCCAAGCGCTACAACAG CGGCAAGCTGGAGGAGTTCGTGCAGGGCAACCTGGAGCGCGAGTGCATGGAGGAGAAGTGCAGCTTCGAGGAGGCCCGCGAGGTGTTCGAGAACACCGAGCG CACCACCGAGTTCTGGAAGCAGTACGTGGACGGCGACCAGTGCGAGAGCAAC CCCTGCCTGAACGGCGGCAGCTGCAAGGACGACATCAACAGCTACGAGTGCT GGTGCCCCTTCGGCTTCGAGGGCAAGAACTGCGAGCTGGACGTGACCTGCAA CATCAAGAACGGCCGCTGCGAGCAGTTCTGCAAGAACAGCGCCGACAACAAG GTGGTGTGCAGCTGCACCGAGGGCTACCGCCTGGCCGAGAACCAGAAGAGCT GCGAGCCCGCCGTGCCCTTCCCCTGCGGCCGCGTGAGCGTGAGCCAGACCAG CAAGCTGACCCGCGCCGAGGCCGTGTTCCCCGACGTGGACTACGTGAACAGCA CCGAGGCCGAGACCATCCTGGACAACATCACCCAGAGCACCCAGAGCTTCAAC GACTTCACCCGCGTGGTGGGCGGCGAGGACGCCAAGCCCGGCCAGTTCCCCT GGCAGGTGGTGCTGAACGGCAAGGTGGACGCCTTCTGCGGCGGCAGCATCGT GAACGAGAAGTGGATCGTGACCGCCGCCCACTGCGTGGAGACCGGCGTGAAG ATCACCGTGGTGGCCGGCGAGCACAACATCGAGGAGACCGAGCACACCGAGC AGAAGCGCAACGTGATCCGCATCATCCCCCACCACAACTACAACGCCGCCATCA ACAAGTACAACCACGACATCGCCCTGCTGGAGCTGGACGAGCCCCTGGTGCTG AACAGCTACGTGACCCCCATCTGCATCGCCGACAAGGAGTACACCAACATCTTC CTGAAGTTCGGCAGCGGCTACGTGAGCGGCTGGGGCCGCGTGTTCCACAAGG GCCGCAGCGCCCTGGTGCTGCAGTACCTGCGCGTGCCCCTGGTGGACCGCGCC ACCTGCCTGCTGAGCACCAAGTTCACCATCTACAACAACATGTTCTGCGCCGGC TTCCACGAGGGCGGCCGCGACAGCTGCCAGGGCGACAGCGGCGGCCCCCAC GTGACCGAGGTGGAGGGCACCAGCTTCCTGACCGGCATCATCAGCTGGGGCG AGGAGTGCGCCATGAAGGGCAAGTACGGCATCTACACCAAGGTGAGCCGCTA CGTGAACTGGATCAAGGAGAAGACCAAGCTGACCTAA

The invention has the advantages of novelty and generated technical effects:

the invention uses the optimized Kozak sequence and gene coding sequence to obviously improve the expression level of the human blood coagulation factor FIX gene. The Kozak sequence and the optimized human FIX gene can be used for efficiently producing FIX protein for treating hemophilia B, and the production cost of the FIX protein is reduced; can also be used for treating hemophilia B by adeno-associated virus (AAV) -mediated gene therapy, and can increase expression level of FIX gene in human body, thereby reducing administration dosage and improving therapeutic effect.

Drawings

FIG. 1 is a schematic diagram of a plasmid in example 1 of the present invention;

FIG. 2 is the FIX concentration of example 1 of the present invention;

FIG. 3 is a schematic diagram of a target plasmid in example 1 of the present invention;

FIG. 4 is a diagram showing the detection of the concentration of FIX protein by the ELISA method according to example 1 of the present invention;

FIG. 5 is a diagram showing the detection of the concentration of FIX protein in the culture medium by the ELISA method according to example 1 of the present invention.

The specific implementation mode is as follows:

the test methods used in the following examples are all conventional methods unless otherwise specified.

Materials, reagents and the like used in the following examples are commercially available unless otherwise specified. The following examples facilitate a better understanding of the invention, but do not limit the invention.